Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 mars 2022 07h00 HE | Source: Alladapt Immunotherapeutics Inc.

Alladapt Announces Initiation of Encore Open-Label Extension Study for its Harmony Phase 1/2 Study of ADP101 for Treatment of Food Allergy

MENLO PARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
04 janv. 2022 07h00 HE | Source: Alladapt Immunotherapeutics Inc.

Alladapt Announces Completion of Patient Enrollment in its Phase 1/2 Harmony Study of ADP101 for Treatment of Food Allergy

MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to...
19 août 2021 07h00 HE | Source: Alladapt Immunotherapeutics Inc.

Alladapt Initiates Buildout of New Manufacturing Facility for Production of Novel, Investigational Oral Immunotherapeutic Designed to Address a Broad Range of Food Allergies

ADP101 is a singular optimized, pharmaceutical-grade oral immunotherapy candidate currently in a Phase 1/2 clinical trial for patients with mono- and multi-food allergies Facility intended to support...
22 juin 2021 07h00 HE | Source: Alladapt Immunotherapeutics Inc.

Alladapt Appoints Glenn Reicin as Chief Financial Officer

MENLO PARK, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to...

Page précédente